Skip to main content
  • Fourth Sartan Carcinogen; Vacation MI; N=1 Trials

    Recent developments of interest in cardiovascular medicine

    fourth type of carcinogen -- the solvent N,N-Dimethylformamide -- has been reported in valsartan (the third type was reported in March). While within the FDA's "safe" threshold, the citizen's petition by online pharmacy Valisure called for action because that limit is way out of line with other sartan contaminants. (Cardiovascular Businessin-PharmaTechnologist)

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details